{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:34:26Z","timestamp":1771295666410,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s43440-020-00175-2","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T13:03:38Z","timestamp":1603803818000},"page":"1542-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Favipiravir use for SARS CoV-2 infection"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-0238","authenticated-orcid":false,"given":"Alberto","family":"Boretti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"175_CR1","doi-asserted-by":"publisher","unstructured":"Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, Bhatia S, Boonyasiri A, Cucunuba Perez ZU, Cuomo-Dannenburg G, Dighe A. Report 9: impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. https:\/\/doi.org\/10.25561\/77482.","DOI":"10.25561\/77482"},{"key":"175_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.14.20062463v1.full.pdf","author":"E Bendavid","year":"2020","unstructured":"Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, Lai C, Weissberg Z, Saavedra R, Tedrow J, Tversky D. COVID-19 antibody seroprevalence in Santa Clara County, California. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.14.20062463v1.full.pdf.","journal-title":"MedRxiv."},{"issue":"7","key":"175_CR3","doi-asserted-by":"publisher","first-page":"233339282093232","DOI":"10.1177\/2333392820932324","volume":"16","author":"A Boretti","year":"2020","unstructured":"Boretti A. After less than 2 months, the simulations that drove the world to strict lockdown appear to be wrong, the same of the policies they generated. Health Serv Res Manag Epidemiol. 2020a;16(7):2333392820932324. https:\/\/doi.org\/10.1177\/2333392820932324.","journal-title":"Health Serv Res Manag Epidemiol"},{"issue":"22","key":"175_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jgar.2020.07.014","volume":"1","author":"A Boretti","year":"2020","unstructured":"Boretti A. COVID-19 fatality rate for Saudi Arabia, updated 3 June 2020. J Glob Antimicrob Resist. 2020b;1(22):845\u20136. https:\/\/doi.org\/10.1016\/j.jgar.2020.07.014.","journal-title":"J Glob Antimicrob Resist"},{"key":"175_CR5","unstructured":"https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_4#:~:text=For%20COVID%2D19%2C,infections%2C%20requiring%20ventilation. Accessed 3 June 2020."},{"key":"175_CR6","unstructured":"https:\/\/www.worldlifeexpectancy.com\/cause-of-death\/influenza-pneumonia\/by-country\/. Accessed 3 June 2020."},{"key":"175_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.15342\/ijms.7.172","volume":"7","author":"A Boretti","year":"2020","unstructured":"Boretti A. Sustainable post Covid19 lockdown strategy through evidence-based policy: analysis of Covid19 fatalities across Europe. Integr J Med Sci. 2020c;7:172. https:\/\/doi.org\/10.15342\/ijms.7.172.","journal-title":"Integr J Med Sci"},{"key":"175_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.15342\/ijms.7.174","volume":"7","author":"A Boretti","year":"2020","unstructured":"Boretti A. Analysis of the Charles De Gaulle aircraft carrier Covid19 epidemic: infectivity and fatality in the young, healthy, active population: lesson from the Charles de Gaulle aircraft carrier Covid19 experience. Integr J Med Sci. 2020d;7:174. https:\/\/doi.org\/10.15342\/ijms.7.174.","journal-title":"Integr J Med Sci"},{"key":"175_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.15342\/ijms.7.179","volume":"7","author":"A Boretti","year":"2020","unstructured":"Boretti A. Some doubt the Covid19 containment measures on the generally healthy population made any difference for Italy: Covid19 fatalities much larger in Europe, United States and Canada than elsewhere. Integr J Med Sci. 2020e;7:179. https:\/\/doi.org\/10.15342\/ijms.7.179.","journal-title":"Integr J Med Sci"},{"key":"175_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)31180-6.","journal-title":"Lancet"},{"key":"175_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31324-6","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)31324-6.","journal-title":"Lancet"},{"key":"175_CR12","doi-asserted-by":"crossref","unstructured":"Piller C, Servick K. Two elite medical journals retract coronavirus papers over data integrity questions. Science. 2020 (10.1126). https:\/\/www.sciencemag.org\/news\/2020\/06\/two-elite-medical-journals-retract-coronavirus-papers-over-data-integrity-questions. Accessed 5 June 2020","DOI":"10.1126\/science.abd1697"},{"key":"175_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1844","author":"YX Du","year":"2020","unstructured":"Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020a. https:\/\/doi.org\/10.1002\/cpt.1844.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"175_CR14","doi-asserted-by":"publisher","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","volume":"8","author":"Z Jin","year":"2013","unstructured":"Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase. PLoS ONE. 2013;8(7):e68347.","journal-title":"PLoS ONE"},{"key":"175_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa171","author":"EA Coomes","year":"2020","unstructured":"Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020. https:\/\/doi.org\/10.1093\/jac\/dkaa171.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"175_CR16","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1128\/JVI.02346-12","volume":"87","author":"T Baranovich","year":"2013","unstructured":"Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol. 2013;87(7):3741\u201351.","journal-title":"J Virol"},{"key":"175_CR17","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"22","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;22:107512.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"175_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","volume":"82","author":"Y Furuta","year":"2009","unstructured":"Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95\u2013102.","journal-title":"Antiviral Res"},{"issue":"8","key":"175_CR19","doi-asserted-by":"publisher","first-page":"e00766\u201318","DOI":"10.1128\/AAC.00766-18","volume":"62","author":"JJ Yoon","year":"2018","unstructured":"Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018;62(8):e00766\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"175_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013;100(2):446\u201354.","journal-title":"Antivir Res"},{"issue":"10","key":"175_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","volume":"221","author":"Y Wang","year":"2020","unstructured":"Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis. 2020;221(10):1688\u201398.","journal-title":"J Infect Dis"},{"issue":"3","key":"175_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269\u201371.","journal-title":"Cell Res"},{"key":"175_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00016-0","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020. https:\/\/doi.org\/10.1038\/d41573-020-00016-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"175_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58\u201360.","journal-title":"Drug Discov Ther"},{"key":"175_CR25","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200416131117","author":"M Costanzo","year":"2020","unstructured":"Costanzo M, De Giglio MA, Roviello GN. SARS-CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 2020. https:\/\/doi.org\/10.2174\/0929867327666200416131117.","journal-title":"Curr Med Chem"},{"key":"175_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007.","journal-title":"Engineering"},{"issue":"2","key":"175_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","volume":"6","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir\u2014a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45.","journal-title":"J Virus Erad"},{"key":"175_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1878","author":"YX Du","year":"2020","unstructured":"Du YX, Chen XP. Response to \u201cDose rationale for favipiravir use in patients infected with SARS-CoV-2.\u201d Clin Pharmacol Ther. 2020b. https:\/\/doi.org\/10.1002\/cpt.1878.","journal-title":"Clin Pharmacol Ther"},{"key":"175_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1877","author":"P Eloy","year":"2020","unstructured":"Eloy P, Solas C, Touret F, Mentr\u00e9 F, Malvy D, de Lamballerie X, Guedj J. Dose rationale for favipiravir use in patients infected with SARS-CoV-2. Clin Pharmacol Ther. 2020. https:\/\/doi.org\/10.1002\/cpt.1877.","journal-title":"Clin Pharmacol Ther"},{"key":"175_CR30","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"3","author":"KT Choy","year":"2020","unstructured":"Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KP, Chu DK, Chan MC, Cheung PP, Huang X, Peiris M. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir Res. 2020;3:104786.","journal-title":"Antivir Res"},{"key":"175_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.17.2003743","author":"C Chen","year":"2020","unstructured":"Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Zhang J, Yin P. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.17.2003743.","journal-title":"MedRxiv"},{"key":"175_CR32","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/who_table. Accessed 3 Oct 2020."},{"key":"175_CR33","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Favipiravir&cntry=&state=&city=&dist=. Accessed 3 Oct 2020."}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00175-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:24:07Z","timestamp":1744079047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00175-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00175-2","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author received no funding and has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}